# lung adenocarcinoma (LUAD) - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 34541
- Completion tokens: 19755
- Reasoning tokens: 10328
- Total tokens: 54296
- API requests reported: 3
- Elapsed seconds: 159.53
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: OpenAI

---
## Data-quality warning first

The uploaded survival statistics are technically suspicious: many genes have saturated values such as **HR = 5.1847055e+21, P = 0, FDR = 0**, and one transcript group, **Y_RNA**, has a reported **direction conflict across 163 rows**. This pattern is consistent with possible complete/quasi-complete survival separation, sparse-expression artifacts, duplicate/probe-level issues, sex-linked confounding, or numerical underflow. Therefore, the **direct cohort evidence supports associations**, but the **magnitude of many HRs should not be interpreted literally**. Also, **external statistical validation was not performed**; database, pathway, STRING, and literature records are contextual evidence only.

## 1. Overall biological interpretation

Across the interpretable subset of genes, worse OS in LUAD tumor tissue is most coherently associated with a combination of:

- **Developmental/Wnt and transcriptional reprogramming**, represented by risk-associated **DKK1, TLE1, PITX3, VAX1, LDLRAD3**, and supported by supplied GO/KEGG terms including **regulation of Wnt signaling pathway**, **positive regulation of Wnt signaling**, **planar cell polarity**, and **Wnt signaling pathway**.
- **Motility, cytoskeletal, junctional, and invasive-state biology**, represented by **RHOF, KRT6A, ITGB1-DT, FUT4, DKK1**, and pathway support for **cell junction disassembly** plus QuickGO evidence linking **RHOF** to actin organization, cell migration, and small GTPase signaling.
- **Cell-surface glycosylation/glycan remodeling**, mainly through risk-associated **FUT4** and protective-associated **CMAHP**, with KEGG support for **mannose type O-glycan biosynthesis** and **glycosphingolipid biosynthesis**.
- **GPCR/G-protein and small GTPase signaling**, represented by risk-associated **RGS20** and **RHOF**, with Reactome/QuickGO/STRING evidence connecting RGS20 to G-alpha signaling and G-protein regulators.
- A large **noncoding, pseudogene, Y-linked/testis-associated, and low-annotation transcript signal**, including **RBMY1F, FAM9A, RBMY2AP, TTTY4C, CDY10P, USP9YP3, TEX13A, MIR509-1, FAS-AS1**, and many RP11/CTD/LOC/unmapped transcripts. This is a major statistical feature but a weaker mechanistic program because it may reflect sex, sparse expression, annotation ambiguity, or technical effects.

Overall, the most biologically plausible exploratory model is that **poor OS is associated with developmental plasticity, Wnt/junctional remodeling, invasive cytoskeletal signaling, and altered tumor-cell surface state**, but this must be validated independently and adjusted for clinical and technical confounders.

## 2. Core biological programs

| Program | Direction / prognostic association | Major supporting genes | Standard pathway / ontology support | Interpretation and evidence strength |
|---|---:|---|---|---|
| **Wnt/developmental transcriptional remodeling** | Mostly risk-associated | **DKK1** HR 1.475, **TLE1** HR 1.484, **PITX3** HR 1.429, **VAX1** HR 1.335, **LDLRAD3** HR 1.420 | GO: regulation/positive regulation of Wnt signaling; GO: planar cell polarity; KEGG: Wnt signaling pathway | Strongest coherent biological program among interpretable genes. DKK1, TLE1, PITX3, and VAX1 collectively suggest developmental-pathway rewiring rather than isolated single-gene effects. Limitation: pathway recurrence is contextual, not formal enrichment, and Wnt “activation” cannot be inferred from HRs alone. |
| **Cell migration, cytoskeleton, adhesion, and junction disassembly** | Risk-associated | **RHOF** HR 1.403, **KRT6A** HR 1.390, **ITGB1-DT** HR 1.302, **FUT4** HR 1.403, **DKK1** HR 1.475 | GO: cell junction disassembly; RHOF QuickGO: actin filament organization, cell migration, regulation of small GTPase signaling | Supported hypothesis. RHOF provides direct cytoskeletal/migration annotation; KRT6A suggests epithelial stress/basal-like state; ITGB1-DT links to integrin-associated biology. PMID:34906142 reports an **ITGB1-DT/ARNTL2** LUAD biomarker axis, but this is not independent validation of the present OS association. |
| **Cell-surface glycosylation and glycan remodeling** | Mixed, mainly risk through FUT4; protective through CMAHP | **FUT4** HR 1.403, **CMAHP** HR 0.7055, possibly **RHCG** HR 1.290 | KEGG: mannose type O-glycan biosynthesis; KEGG: glycosphingolipid biosynthesis; STRING links FUT4 with **B3GNT3** and **B4GALT1** | Biologically plausible but moderate evidence. FUT4 and CMAHP point toward altered glycan/sialic-acid biology that could affect adhesion, receptor signaling, or immune recognition. Limitation: only a small number of interpretable genes drive this program, and transcript data do not directly measure glycan structures. |
| **GPCR/G-protein and small GTPase signaling** | Risk-associated | **RGS20** HR 1.352, **RHOF** HR 1.403 | RGS20 QuickGO: GTPase activity, GTPase activator activity, protein binding; Reactome: G alpha i/z signaling events; STRING: RGS20 associations with **GNAZ, GNB5, GNAI2, GNAQ** | Exploratory but mechanistically coherent. RGS20 and RHOF both implicate signal-transduction nodes that can regulate motility, growth, or survival. Limitation: STRING interactions are functional/source-dependent and mostly connect to genes not selected in the uploaded list, so this is not yet a demonstrated LUAD survival module. |
| **Sparse noncoding/Y-linked/testis-associated transcript signal** | Predominantly risk-associated; some extreme protective outliers | **RBMY1F**, **FAM9A**, **RBMY2AP**, **TTTY4C**, **CDY10P**, **USP9YP3**, **TEX13A**, **MIR509-1**, **FAS-AS1**, many RP11/CTD/LOC transcripts; protective **TCP10L3**, **RBMXP1**, **CRNDE**, **CMAHP** | No single robust standardized pathway; supplied Reactome RNA Pol II/CTD recurrence appears weak and may be annotation/name-driven | Important statistical pattern but weak mechanistic evidence. The extreme HRs and many poorly annotated transcripts make this a priority for QC and confounding checks rather than a confident biological program. |

## 3. Key genes or interaction modules to prioritize

| Candidate | Dataset association | Role in core programs | Relationship type and evidence |
|---|---:|---|---|
| **DKK1** | Risk, HR 1.475, FDR 3.547e-07 | Wnt/developmental and junctional remodeling | **Pathway co-membership/contextual pathway evidence** with Wnt-related GO/KEGG terms; not evidence of direct physical interaction with other selected genes. |
| **TLE1** | Risk, HR 1.484, FDR 2.457e-05 | Developmental transcriptional regulation | Likely **regulatory/pathway-level relationship** with developmental programs; direct interaction evidence was not supplied. |
| **PITX3 / VAX1 module** | Risk: PITX3 HR 1.429; VAX1 HR 1.335 | Homeobox/developmental-state signal | **Putative regulatory module** based on gene class and shared association direction; insufficient evidence for direct interaction. |
| **RHOF** | Risk, HR 1.403, FDR 0.0003997 | Motility, cytoskeleton, small GTPase signaling | QuickGO supports actin/migration/small GTPase biology. STRING links include **ACTN1** and **ARHGAP1**, best treated as **functional/pathway or predicted interaction evidence**, not confirmed direct physical interaction. |
| **RGS20** | Risk, HR 1.352, FDR 0.0005793 | GPCR/G-protein signaling | QuickGO and Reactome support GTPase/G-alpha signaling. STRING links to **GNAZ, GNB5, GNAI2, GNAQ** are **network/functional associations**; direct binding requires experimental confirmation. |
| **FUT4** | Risk, HR 1.403, FDR 0.0002935 | Glycosylation and cell-surface remodeling | KEGG glycan pathway support; STRING links to **B3GNT3/B4GALT1** indicate **pathway co-membership or functional association**, not necessarily direct physical interaction. |
| **CMAHP** | Protective, HR 0.7055, FDR 0.0005772 | Glycan/sialic-acid biology | Protective direction contrasts with risk-associated FUT4, suggesting glycan biology may be heterogeneous. Mechanistic interpretation remains exploratory without glycomic validation. |
| **KRT6A** | Risk, HR 1.390, FDR 0.0002784 | Epithelial stress, basal-like differentiation, possible invasive phenotype | Best interpreted as **cell-state/composition-associated evidence** rather than a causal driver unless validated by tumor-cell-specific assays. |
| **ITGB1-DT** | Risk, HR 1.302, FDR 0.0001478 | Adhesion/integrin-linked invasive program | Literature supports an **ITGB1-DT/ARNTL2** LUAD biomarker axis (PMID:34906142); relationship is **regulatory/biomarker-level**, not a direct physical interaction. |
| **Y-linked/testis-associated transcript module** | Strong risk, often HR 5.1847055e+21, P/FDR 0 | Possible sex-linked, cancer-testis, or sparse-expression signal | Relationship is **shared annotation/genomic context**, not gene-gene interaction. This module requires sex-stratified and sparse-expression validation before biological interpretation. |

## 4. Validation priorities

| Priority | Class | Why prioritize | Evidence in current dataset | External evidence | Next validation step | Confidence |
|---|---|---|---|---|---|---|
| **Re-run survival modeling with QC and covariate adjustment** | Confounding or composition check | Extreme HRs/P=0/FDR=0 dominate the table and could reflect separation or sparse expression | 96/100 genes are risk-associated; many HRs are 5.1847055e+21; Y_RNA has direction conflict | No independent cohort statistic supplied | Penalized Cox/Firth Cox, expression prevalence filtering, sex/stage/smoking/treatment/tumor-purity covariates, proportional-hazards testing | **Established need; biological conclusions remain exploratory** |
| **Validate the Wnt/developmental program** | Biomarker | Most coherent interpretable program across multiple risk genes | DKK1, TLE1, PITX3, VAX1, LDLRAD3 all risk-associated | GO/KEGG Wnt and planar-cell-polarity evidence; no external OS replication supplied | Test a Wnt/developmental score in independent LUAD OS cohorts; multivariable Cox; spatial/IHC confirmation | **Supported hypothesis** |
| **Test motility/invasion biology involving RHOF–KRT6A–ITGB1-DT** | Mechanistic hypothesis | Links poor OS to migration, cytoskeleton, adhesion, and epithelial stress state | RHOF, KRT6A, ITGB1-DT risk-associated | RHOF QuickGO/STRING support; PMID:34906142 supports ITGB1-DT as LUAD biomarker context | Knockdown/overexpression in LUAD models; invasion assays; spatial transcriptomics for tumor vs stromal localization | **Supported but not causal** |
| **Interrogate glycan remodeling through FUT4/CMAHP** | Mechanistic hypothesis | Glycosylation can influence adhesion, immune recognition, and receptor signaling, but transcript evidence is indirect | FUT4 risk-associated; CMAHP protective-associated | KEGG glycan pathway support; STRING FUT4 glycosylation-network links | Glycomics or lectin profiling; FUT4 perturbation; immune-cell and mucin-state correlation | **Exploratory hypothesis** |
| **Clarify GPCR/G-protein signaling around RGS20 and RHOF** | Interaction / network hypothesis | Provides a signaling route that could connect receptor cues to cytoskeletal behavior | RGS20 and RHOF risk-associated | RGS20 QuickGO/Reactome/STRING support; RHOF QuickGO migration/GTPase support | Validate expression-protein concordance, G-protein pathway activity, and perturbation effects on proliferation/migration | **Exploratory hypothesis** |

No current result should be treated as an established therapeutic target. Drug or target-database coverage in the evidence pack is contextual only and does not demonstrate clinical efficacy in LUAD.

## 5. Main limitations and alternative explanations

1. **Statistical degeneracy / survival separation**: HRs such as **5.1847055e+21** with **P=0/FDR=0** are unlikely to be stable effect estimates; re-analysis with penalized survival models and expression-prevalence filters is essential.  
2. **Sex-linked confounding**: Many top risk transcripts are Y-linked or testis-associated, so male sex, sex-chromosome expression, or sample imbalance could masquerade as prognosis. Test sex-stratified models and sex-adjusted Cox models.  
3. **Tumor purity and cell composition**: KRT6A, glycan genes, and motility genes may reflect epithelial subtype, squamous-like contamination, stromal admixture, or invasive tumor regions. Use deconvolution, pathology purity, and spatial/IHC validation.  
4. **Annotation and noncoding-transcript ambiguity**: Many RP11/CTD/LOC/unmapped transcripts have limited functional annotation; pathway hits involving CTD-like names should be treated cautiously unless gene mapping is confirmed.  
5. **Association-versus-causation**: The dataset supports OS associations, not causal mechanisms. Functional perturbation and independent LUAD cohort validation are required before claiming driver biology or therapeutic relevance.

In summary, the most defensible interpretation is an **exploratory poor-prognosis LUAD signature dominated by suspicious sparse/noncoding signals but containing plausible biological axes involving Wnt/developmental remodeling, invasion/cytoskeletal signaling, glycan remodeling, and GPCR/GTPase signaling**.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=33, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
